Equities

GeoVax Labs Inc

GeoVax Labs Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.70
  • Today's Change0.09 / 3.45%
  • Shares traded5.14k
  • 1 Year change-65.38%
  • Beta3.2477
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year GeoVax Labs Inc's revenues fell -100.00% from 81.53k to 0.00. has fallen 85.20% from a loss of 14.02m to a larger loss of 25.97m.
Gross margin--
Net profit margin-787.08%
Operating margin-792.63%
Return on assets-178.10%
Return on equity-276.02%
Return on investment-276.02%
More ▼

Cash flow in USDView more

In 2023, cash reserves at GeoVax Labs Inc fell by 21.16m. Cash Flow from Financing totalled 4.06m or -- of revenues. In addition the company used 25.17m for operations while cash used for investing totalled 48.95k.
Cash flow per share-7.29
Price/Cash flow per share--
Book value per share0.9878
Tangible book value per share0.9878
More ▼

Balance sheet in USDView more

GeoVax Labs Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio4.17
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.